Methylprednisolone

Methylprednisolone

Form: Injectable (IV/IM) – powder for solution

Strength: 40 mg, 125 mg, 500 mg, 1 g vials

Reference Brands: Solu-Medrol (US & EU)

Category: Critical Care

Methylprednisolone is a potent corticosteroid used to manage inflammation in conditions such as autoimmune diseases, allergies, asthma, and acute spinal cord injuries. It is available in injectable forms (40 mg to 1 g vials) and oral tablets (2–32 mg). In the US and EU, Solu-Medrol and Medrol by Pfizer are leading brands, along with widely available generics from Sandoz, Teva, Accord, and others. Methylprednisolone offers fast, reliable immunosuppressive and anti-inflammatory effects. Pharma B2B platforms enable bulk procurement of Methylprednisolone for hospitals, emergency services, and critical care settings requiring high-quality steroid solutions.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more